Through multiple mechanisms—including blocking oncogenic pathways to inhibit proliferation (core pathway: Wnt/β-catenin), reversing the EMT phenotype to suppress metastasis, and overcoming immune evasion and drug resistance to promote apoptosis—BBR effectively curbs Fn-driven tumor malignant progression, metastasis, and therapeutic resistance. The gene discussed is FN1; the disease is neoplasm.